Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $84.54, for a total value of $253,620.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Clovis Oncology, Inc. (NASDAQ CLVS) opened at 78.72 on Thursday. The company’s market capitalization is $3.85 billion. The stock has a 50 day moving average price of $77.57 and a 200 day moving average price of $71.40. Clovis Oncology, Inc. has a 1-year low of $25.81 and a 1-year high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by ($0.02). The firm had revenue of $14.62 million for the quarter, compared to the consensus estimate of $13.07 million. During the same quarter in the previous year, the company earned ($2.07) earnings per share. The company’s revenue for the quarter was down 32.5% on a year-over-year basis. Analysts forecast that Clovis Oncology, Inc. will post ($7.55) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Gillian C. Ivers-Read Sells 3,000 Shares of Clovis Oncology, Inc. (CLVS) Stock” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/10/19/gillian-c-ivers-read-sells-3000-shares-of-clovis-oncology-inc-clvs-stock.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its holdings in shares of Clovis Oncology by 0.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 20 shares during the period. Hanseatic Management Services Inc. increased its holdings in shares of Clovis Oncology by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 13,693 shares of the biopharmaceutical company’s stock worth $1,282,000 after purchasing an additional 37 shares during the period. Aperio Group LLC increased its holdings in shares of Clovis Oncology by 1.7% during the second quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 83 shares during the period. Clough Capital Partners L P increased its holdings in shares of Clovis Oncology by 0.6% during the first quarter. Clough Capital Partners L P now owns 15,900 shares of the biopharmaceutical company’s stock worth $1,012,000 after purchasing an additional 100 shares during the period. Finally, Greenwood Capital Associates LLC increased its holdings in shares of Clovis Oncology by 4.0% during the second quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock worth $514,000 after purchasing an additional 212 shares during the period. 98.94% of the stock is currently owned by institutional investors.

Several equities analysts recently weighed in on CLVS shares. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research report on Tuesday. Cann reissued a “hold” rating on shares of Clovis Oncology in a research report on Monday, July 31st. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, October 10th. Bank of America Corporation reissued a “buy” rating on shares of Clovis Oncology in a research report on Thursday, August 3rd. Finally, J P Morgan Chase & Co reissued an “overweight” rating on shares of Clovis Oncology in a research report on Tuesday, August 1st. Eight investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $86.47.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.